sanofi-aventis

  • 2010

    8. juni 2010:Pressemeddelelse nr. 5, 2010: Zealand Pharma Announces An Extension of The Lixisenatide...

    Read More >

  • Meet us

    The 31st European Peptide Symposium, Copenhagen, Denmark, 5-9 September 2010 (Science) 46th An...

    Read More >

sanofi-aventis

In June 2003 Sanofi Deutschland GmbH (now sanofi-aventis Deutschland GmbH) and Zealand Pharma completed an agreement that granted sanofi-aventis Deutschland GmbH exclusive, worldwide rights to develop, manufacture and market Lixisenatide (ZP10, AVE0010), a GLP-1 agonist for the treatment of Type 2 diabetes. At that point in time Lixisenatide was in Phase I/II clinical trial.

In May 2008, sanofi-aventis started its first Phase III clinical trial for the compound and the product is expected to be launched in 2013. In October 2009, sanofi-aventis initiated Phase I clinical development for a combination of the recombinant human insulin Lantus® and Lixisenatide.

To top of page

Tip a friend

Fill in the form below to tip a friend about this page.






Subscribe

When this page is updated you will be updated by e-mail.



Related links